The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia
Jazyk angličtina Země Itálie Médium electronic
Typ dokumentu dopisy, Research Support, N.I.H., Extramural
Grantová podpora
U10 CA180886
NCI NIH HHS - United States
U10 CA180899
NCI NIH HHS - United States
PubMed
32381579
PubMed Central
PMC7849578
DOI
10.3324/haematol.2019.236745
PII: haematol.2019.236745
Knihovny.cz E-zdroje
- MeSH
- akutní myeloidní leukemie * genetika MeSH
- dítě MeSH
- fúzní onkogenní proteiny genetika metabolismus MeSH
- homeodoménové proteiny genetika MeSH
- komplex proteinů jaderného póru * genetika MeSH
- lidé MeSH
- translokace genetická MeSH
- vazebný protein 2 retinoblastomu MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- dopisy MeSH
- Research Support, N.I.H., Extramural MeSH
- Názvy látek
- fúzní onkogenní proteiny MeSH
- homeodoménové proteiny MeSH
- KDM5A protein, human MeSH Prohlížeč
- komplex proteinů jaderného póru * MeSH
- nuclear pore complex protein 98 MeSH Prohlížeč
- Nup98 protein, human MeSH Prohlížeč
- vazebný protein 2 retinoblastomu MeSH
AML BFM Study Group Pediatric Hematology and Oncology Essen Germany
Children's Oncology Group Monrovia California USA
CPH University Hospital Motol and Charles University Prague Czech Republic
Department of Pediatrics Seattle Children's Hospital University of Washington Seattle USA
Fred Hutchinson Cancer Research Center Seattle Washington USA
IRCCS Ospedale Bambino Gesú Sapienza University of Rome Rome Italy
Pediatric Oncology Hematology Erasmus MC Sophia Children Hospital Rotterdam The Netherlands
Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands
University Hospital Robert Debré and Paris Diderot University Paris France
Zobrazit více v PubMed
Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015; 33(27):2949-2962. PubMed PMC
Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol Oncol Clin North Am. 2010;24(1):35-63. PubMed
Balgobind BV, Hollink IH, Arentsen-Peters ST, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 2011;96(10):1478-1487. PubMed PMC
Coenen EA, Raimondi SC, Harbott J, et al. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood. 2011;117(26):7102-7111. PubMed PMC
de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: from biology to clinical management. J Clin Med. 2015;4(1):127-149. PubMed PMC
Niktoreh N, Walter C, Zimmermann M, et al. Mutated WT1, FLT3- ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia. J Oncol. 2019;2019:1609128. PubMed PMC
Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118(13):3645-3656. PubMed
de Rooij JD, Hollink IH, Arentsen-Peters ST, et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia. 2013;27(12):2280-2288. PubMed
Bolouri H, Farrar JE, Triche T, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103-112. PubMed PMC
Struski S, Lagarde S, Bories P, et al. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia. 2017;31(3):565-572. PubMed
Bisio V, Zampini M, Tregnago C, et al. NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group. Leukemia. 2017;31(4):974-977. PubMed
McCowage GB, Mueller S, Pratilas CA, et al. Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study. J Clin Oncol. 2018;36(15_suppl): 10504-10504.
Aplenc R, Meshinchi S, Sung L, et al. The addition of bortezomib to standard chemotherapy for pediatric acute myeloid leukemia has increased toxicity without therapeutic benefit: a report from the Children's Oncology Group. Blood. 2016;128(22):899.
